Please see enclosed annexure

July 24, 2026 To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS Dear Sir / Madam, Sub: Approval of Unaudited Financial Results for the quarter ended June 30, 2026 Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026 at their meeting held today, i.e., July 24, 2026, which are annexed herewith along with Limited Review Reports issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company. The financial results are also available on the website of the Company at www.lauruslabs.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com, respectively. The Board Meeting commenced at 02.00 p.m. IST and concluded at 02.42 p.m. IST. This is for your information and records. Thanking you, Yours sincerely, For Laurus Labs Limited G. Venkateswar Reddy Company Secretary & Compliance Officer Encl: A/a LAURUSLabs Chemistry for Better Living LAURUSLABSL~ITED (CIN: L24239AP2005PLOJ47518) Regd.Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandai, Anakapalli District, Andhra Pradesh-531021 Corp. Office: Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India. Tel: +91 040 6659 4333; Fax: +91 040 6659 4320; E-mail: sec:retarial@lauruslabs.com; Website: www.lauruslabs.com STATEMENT OF CONSOLIDATED UNAUDITED FINANOAL RESULTS FOR THE QUARTER ENDED JUNE 30,2026 ? in Crc;res Quarter ended Year ended Particulars 3D-Jun-26 31-Mar-26 3D-Jun-25 31-Mar-26 (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Income (a) Revenue from operations 2,026.31 1,811.57 1,569.57 6,812.90 (b) Other income 9.18 11.80 1Q.43 54.95 Total income 2,035.49 1)123.37 1,580.00 6)167.85 2 Expenses (a) Cost of materials consumed 785.77 792.86 599.41 2,794.34 (b) Purchase of traded goods 35.12 48.24 38.50 172.56 {c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (64.88) (141.00) (0.56) (271.44) {d) Employee benefits expense 258.70 235.85 214.80 895.45 {e) Other expenses 373.33 363.51 335.29 1,444.28 {f) Depreciation and amortisation expense 123.87 122.10 116.84 480.05 {g) Finance costs 42.22 40.44 51.50 170.73 Total expenses 1,554.13 1,462.00 1,355.78 5,685.97 3 Profit before tax (1-2) 481.36 361.37 224.22 1,181.88 4 Tax expense (a) Current tax 134.88 78.13 60.02 297.52 (b) Deferred tax (15.51) 1.33 3.12 (5.49\ Total Tax expense 119.37 79.46 63.14 292.03 5 Net Profit after tax (3-4) 361.99 281.91 161.08 889.85 6 Share of net profit from associates and joint venture, net of tax 0.08 0.18 0.60 0.29 7 Net Profit after taxes and share of net profit from associates and joint venture 362.07 282.09 161.68 890.14 8 Other comprehensive incom<if(loss) (a) Items that will not be reclassified subsequently to profit or loss: {i) Remeasurement gains/ {losses) on defined benefit plans (2.42) 6.45 (0.25) 3.64 {ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods 0.61 (1.62) 0.06 (0.91) (iii) Share in Other comprehensive income of associates and joint venture, net of tax . 0.12 - 0.11 (b) Items that will be reclassified subsequently to profit or loss: Exchange differences on translating the financial statements of foreign operations (0.40) (2.87) (0.52) (8.74) Total other comprehensive incomef(loss), net of tax (2.21) 2.08 (0.71) (5.90) 9 Total comprehensive income (7+8) 359.86 284.17 160.97 884.24 10 Profit for the period attributable to: i) Equity holders of the company 367.60 279.14 163.02 888.79 ii) Non-controlling interests (5.53) 2.95 (1.34) 1.35 11 Total comprehensive income for the period attributable to: i) Equity holders of the company 365.39 281.23 162.31 882.90 ii) Non-controlling interests (5.53) 2.94 (1.34) 1.34 12 Paid-up equity share capital (face value { 2/-each) 108.05 107.97 107.96 107.97 13 Other equity 5,192.09 14 Earnings per equity share (face value { 2/-each) ·Basic({) 6.81 5.17 3.02 16.47 -Diluted(~) 6.80 5.17 3.02 16.45 (N01t mm uaUsal) (NotlD1nuRlised) (N<'f~~rmwJli'iCJ) {,.t,tutualiscd) See accompanymg notes to the financ1al results Registered Office Corporate Office Laurus Labs Limited Plot No. 103, Road No.1. Jubilee Hills. Hyderabad, Telangana -500 033. India. Laurus Enclave. Plot Office 01, E. Bonangi Village. Parawada Mandai, Anakapalli District-531021. Andhra Pradesh, India. T +91 40 6659 4333 F +91 40 6659 4320 T +91 891 682 1101. 1102. F +91 891 682 1103 E info@lauruslabs.com, W lauruslabs.com CIN : L24239AP2005PLC047518 LAURUSLabs Chemistry for Better Living Notes: The above consolidated unaudited financial results of Laurus Labs Limited ("the Company") including its subsidiaries (Collectively known as "the Group"), and its associates and joint venture (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on july 24, 2026. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued an unmodified conclusion in respect of the limited review for the quarter ended june 30, 2026. 2 These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards CJnd AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ('SEBI"). The consolidated financial results include the results of the fo1lowin£ entities: Name of the Company Country of Nature of relationship 0/oHolding Incorporation Sriam Labs Private Limited India Subsidiary 100% La urns Holdings Limited UK Subsidiary 100% Laurus Generics Inc USA Step-down subsidiary 100% Laurus Generics GmbH Germany Step-down subsidiary 100% Laurus Synthesis Private Limited India Subsidiary 100% Laurus Generics SA (Pty) Ltd South Africa Subsidiary 100% Laurus Bio Private Limited (Refer note 4b India Subsidiarv 78.34% Laurus Spe:ialtv Chemicals Private Limited (Refer note4a) India Subsidiarv 100% lmmunoAdoptive Cell Therapy Private Limited India Associate 34.89% Ethan Ener£y India Private Limited India Associate 26.00% KRKA Pharma Private Limited (Refer note4c) India Joint Venture 49.00% 4 a) The Company mcorporated wholly owned subs1d1ary, Laurus Speoalty Chenucals Pnvate Linuted (LSCPL) m lndm on December 01, 2022 LSCPL has not commenced its operations. b) During the quarter ended December 31, 2025, the company has invested t 35 Crores into Laurus Bio Private Limited as per the definitive agreement with Laurus Labs Limited (Parent Company), Eight Roads Ventures and F-Prime Capital ('Investors'). c) Pursuant to the joint venture agreement entered into by the Company with KRKA Pharma Private Limited ("KRKA'), Capital contribution of~ 49 Crores have been made into KRKA in terms of the aforesaid agreement during the quarter ended December 31, 2025 for 49% stake. The Company has accounted lor the investment in KRKA as joint venture. Pursuant to investment agreement entered into by the Company with Kumool Renewables Private Umited (Kurnool Renewables), capital contributions have been made into Kumool Renewables in terms of the aforesaid agreement during the quarter ended June 30, 2025 . The Company has accounted for its investment in Kumool Renewables as an associate w.e.f May 12,2025. The Group is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per lnd AS 108-'Operating Segments1• The Board of Directors of the Company, i [Showing first 8,000 characters — download PDF for full document]